---
title: "U.S. stock market update: Incannex Healthcare up 9.37%"
description: "Incannex Healthcare rose 9.37%; Eli Lilly fell 0.80%, with a trading volume of USD 394 million; Novo Nordisk rose 1.80%, with a trading volume of USD 312 million; Johnson & Johnson fell 0.37%, with a "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254472464.md"
published_at: "2025-08-25T14:33:00.000Z"
---

# U.S. stock market update: Incannex Healthcare up 9.37%

> Incannex Healthcare rose 9.37%; Eli Lilly fell 0.80%, with a trading volume of USD 394 million; Novo Nordisk rose 1.80%, with a trading volume of USD 312 million; Johnson & Johnson fell 0.37%, with a trading volume of USD 244 million; AstraZeneca fell 0.59%, with a market capitalization of USD 249.7 billion

**U.S. Stock Market Midday Update**

Incannex Healthcare rose 9.37%, with increased trading volume. Based on recent important news:

1.  On August 22, Incannex Healthcare announced that the board approved a stock repurchase plan of up to $20 million, driving the stock price up by 36.9%.
    
2.  On August 23, the short interest in Incannex Healthcare rose to 82.61%, indicating an increased bearish sentiment in the market regarding its stock.
    
3.  On August 22, the company stated that the repurchase plan would be executed through open market purchases, further enhancing shareholder value.
    

**Stocks with High Trading Volume in the Industry**

Eli Lilly fell 0.80%, with increased trading volume. Based on recent important news:

1.  On August 25, Eli Lilly reached a clinical supply agreement with Immuneering to evaluate the effects of Atebimetinib in combination with Olomorafib, causing stock price fluctuations.
    
2.  On August 23, research indicated that Eli Lilly's Mounjaro drug could reduce cancer risk, leading to a positive market reaction.
    
3.  On August 22, poor trial data for Eli Lilly's obesity drug put pressure on the stock price.
    

Novo Nordisk rose 1.80%, with increased trading volume. Based on recent important news:

1.  On August 25, Novo Nordisk approved the new MASH indication application for semaglutide, promoting industry development and driving the stock price up.
    
2.  On August 23, research showed that GLP-1 drugs reduce cancer risk, boosting market confidence and increasing stock prices.
    
3.  On August 22, Novo Nordisk invested in an expansion project in Tianjin, demonstrating its focus on the Chinese market and enhancing investor confidence.
    

Johnson & Johnson fell 0.37%, with increased trading volume. Based on recent important news:

1.  On August 22, Johnson & Johnson announced a $2 billion investment in North Carolina to expand manufacturing capacity in response to potential drug import tariff policies, causing the stock price to decline.
    
2.  On August 22, Citigroup raised Johnson & Johnson's target stock price to $200, leading to a positive market reaction.
    
3.  On August 22, Johnson & Johnson's new indication application for niraparib and abiraterone was accepted, with the market holding an optimistic view on its prospects.
    

**Stocks with High Market Capitalization in the Industry**

AstraZeneca fell 0.59%, with increased trading volume. Based on recent important news:

1.  On August 22, AstraZeneca announced that its durvalumab was approved domestically for the treatment of certain types of breast cancer, which could boost market confidence but failed to offset overall market pressure.
    
2.  On August 22, AstraZeneca's acquisition of the Chinese business for rosuvastatin received unconditional approval, indicating the company's expansion strategy in the Chinese market.
    
3.  On August 22, AstraZeneca established a research and development center in the Philippines, demonstrating its long-term investment plans in the Asian market

### Related Stocks

- [IXHL.US - Incannex Healthcare](https://longbridge.com/en/quote/IXHL.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 中金公司重申對蔚來汽車 A 類股票（9866）的買入評級 | 中金公司分析師昨日對蔚來汽車（NIO Inc. Class A）維持了買入評級，並設定了 50.00 港元的目標價。情人節促銷 - 70% 折扣解鎖對沖基金級別的數據和強大的投資工具，以便做出更聰明、更精準的決策。通過最新的新聞和分析保持市 | [Link](https://longbridge.com/en/news/275967598.md) |
| 市場監管總局約談阿里巴巴、抖音、百度、騰訊、京東、美團、淘寶閃購等平台企業 | 市場監管總局於 2 月 13 日約談了阿里巴巴、抖音、百度、騰訊、京東、美團和淘寶閃購等平台企業，要求它們遵守相關法律法規，落實主體責任，規範促銷行為，並杜絕 “內卷式” 競爭，以維護公平競爭市場環境，促進平台經濟的創新與健康發展。 | [Link](https://longbridge.com/en/news/275975190.md) |
| 西屋制動｜10-K：2025 財年營收 112 億美元超過預期 |  | [Link](https://longbridge.com/en/news/275943619.md) |
| Research Solutions｜10-Q：2026 財年 Q2 營收 11.79 百萬美元不及預期 |  | [Link](https://longbridge.com/en/news/275943659.md) |
| 羣核科技拿下境外備案，“杭州六小龍” 首家上市公司漸近 |  | [Link](https://longbridge.com/en/news/275974694.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.